First Tracks Biotherapeutics (MEX:TRAX) General and Admin. Expense: MXN Mil (TTM As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:TRAX First Tracks Biotherapeutics Inc MEX:TRAX
12 GF Score
Price MXN800.00
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics General and Admin. Expense?

First Tracks Biotherapeutics MEX:TRAX 12 General and Admin. Expense is MXN Mil as of Dec. 2024. GuruFocus rates MEX:TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. First Tracks Biotherapeutics's General and Admin. Expense for the six months ended in Dec. 2024 was MXN599.73 Mil. First Tracks Biotherapeutics does not have enough years/quarters to calculate the General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024.

First Tracks Biotherapeutics General and Admin. Expense Related Terms

First Tracks Biotherapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics General and Admin. Expense Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
General and Admin. Expense
354.20 599.73

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
General and Admin. Expense 354.20 599.73
MEX:TRAX
12GF Score
First Tracks Biotherapeutics Inc MEX:TRAX
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

What does a General and Admin. Expense of MXN Mil mean?
First Tracks Biotherapeutics (MEX:TRAX) has a General and Admin. Expense of MXN Mil as of Dec. 2024. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' General and Admin. Expense too high?
First Tracks Biotherapeutics' current General and Admin. Expense is MXN Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' General and Admin. Expense compare to AVLN and IMTX?
First Tracks Biotherapeutics' General and Admin. Expense of MXN Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current General and Admin. Expense is MXN Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (MEX:TRAX) has a current General and Admin. Expense of MXN Mil. The current General and Admin. Expense is MXN Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For First Tracks Biotherapeutics (MEX:TRAX), the current General and Admin. Expense is MXN Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USAB43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for MEX:TRAX

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN800.00
Price